Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds.
On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with "generalized myasthenia gravis" who are anti-acetylcholine receptor antibody-positive.
The company said the FDA granted "Priority Review" for the new drug application and set a target action date in November 2026 after the use of a priority review voucher. The biotech firm also expects a European Commission decision in the second half of 2027. The filings are supported by data from the Phase 3 NIMBLE trial ****** sing subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic gMG.
On the same day, RBC Capital maintained a "Sector Perform" rating and a $707 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). However, the firm called AbbVie's acquisition of Apogee Therapeutics a "net negative" for the company. RBC Capital said the deal adds fuel to a potential next-generation competitor to Dupixent. It also adds AbbVie's commercial expertise and longstanding dermatology market relationships behind Apogee's IL-13 antibody program.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology firm. Its brand lineup includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with "generalized myasthenia gravis" who are anti-acetylcholine receptor antibody-positive.
The company said the FDA granted "Priority Review" for the new drug application and set a target action date in November 2026 after the use of a priority review voucher. The biotech firm also expects a European Commission decision in the second half of 2027. The filings are supported by data from the Phase 3 NIMBLE trial ****** sing subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic gMG.
On the same day, RBC Capital maintained a "Sector Perform" rating and a $707 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). However, the firm called AbbVie's acquisition of Apogee Therapeutics a "net negative" for the company. RBC Capital said the deal adds fuel to a potential next-generation competitor to Dupixent. It also adds AbbVie's commercial expertise and longstanding dermatology market relationships behind Apogee's IL-13 antibody program.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology firm. Its brand lineup includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
2 months ago
